Right Dose Right Now:床旁数据驱动的严重脓毒症和脓毒性休克个体化抗生素给药——多中心随机对照优效性试验的原理与设计
针对严重脓毒症或脓毒性休克患者抗生素暴露常不充分的问题,研究者开发了AutoKinetics临床决策支持系统,将电子健康记录数据输入药代动力学模型,在床旁实时显示患者特异性预测血药浓度并给出个体化给药建议。本研究为多中心、随机对照、两臂平行、非盲、优效性试验,计划纳入336例成人ICU患者,评估AutoKinetics对药效学指标(主要终点为首24小时药代动力学目标达成)和临床结局的影响。
要点
- AutoKinetics将电子健康记录数据输入药代动力学模型,床旁实时提供个体化抗生素给药建议。
- 主要终点为前24小时药代动力学目标达成;每组每种抗生素需42例,共纳入336例。
- 次要终点包括目标达成时间、全疗程目标达成比例及死亡率、临床治愈、无器官支持天数。
核心结论
- 这是首个评估床旁数据驱动自动化抗生素给药建议有效性与安全性的随机对照试验,充分抗生素暴露可能对治疗严重脓毒症和脓毒性休克至关重要。
研究设计与样本
- 多中心、随机对照、两臂平行、非盲、优效性试验,计划纳入成人ICU疑似或确诊感染且伴乳酸血症或接受血管升压药支持的患者共336例,每组168例。
主要发现
- 原文未报告试验结果;主要终点为前24小时药代动力学目标达成。
- 次要药代动力学终点包括目标达成时间和全疗程目标达成比例;次要临床终点包括死亡率、临床治愈和无器官支持天数。
关键数值与推荐
- 纳入标准:成人ICU患者,疑似或确诊感染,且伴乳酸血症或接受血管升压药支持。
- 在处方头孢曲松、环丙沙星、美罗培南或万古霉素中至少一种时于床旁随机分组。
- 每组每种抗生素需42例,共336例(每组168例)。
临床怎么用
- AutoKinetics组接受床旁个体化给药建议,对照组接受标准给药方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibiotic exposure is often inadequate in critically ill patients with severe sepsis or septic shock and this is associated with worse outcomes. Despite markedly altered and rapidly changing pharmacokinetics in these patients, guidelines and clinicians continue to rely on standard dosing schemes. To address this challenge, we developed AutoKinetics, a clinical decision support system for antibiotic dosing. By feeding large amounts of electronic health record patient data into pharmacokinetic models, patient-specific predicted future plasma concentrations are displayed graphically. In addition, a tailored dosing advice is provided at the bedside in real time. To evaluate the effect of AutoKinetics on pharmacometric and clinical endpoints, we are conducting the Right Dose Right Now multicenter, randomized controlled, two-arm, parallel-group, non-blinded, superiority trial. METHODS: All adult intensive care patients with a suspected or proven infection and having either lactatemia or receiving vasopressor support are eligible for inclusion. Randomization to the AutoKinetics or control group is initiated at the bedside when prescribing at least one of four commonly administered antibiotics: ceftriaxone, ciprofloxacin, meropenem and vancomycin. Dosing advice is available for patients in the AutoKinetics group, whereas patients in the control group receive standard dosing. The primary outcome of the study is pharmacometric target attainment during the first 24 h. Power analysis revealed the need for inclusion of 42 patients per group per antibiotic. Thus, a total of 336 patients will be included, 168 in each group. Secondary pharmacometric endpoints include time to target attainment and fraction of target attainment during an entire antibiotic course. Secondary clinical endpoints include mortality, clinical cure and days free from organ support. Several other exploratory and subgroup analyses are planned. DISCUSSION: This is the first randomized controlled trial to assess the effectiveness and safety of bedside data-driven automated antibiotic dosing advice. This is important as adequate antibiotic exposure may be crucial to treat severe sepsis and septic shock. In addition, the trial could prove to be a significant contribution to clinical pharmacometrics and serve as a stepping stone for the use of big data and artificial intelligence in the field. TRIAL REGISTRATION: Netherlands Trial Register (NTR), NL6501/NTR6689. Registered on 25 August 2017. European Clinical Trials Database (EudraCT), 2017-002478-37. Registered on 6 November 2017.
引用
- Roggeveen LF, Fleuren LM, Guo T, et al. Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock - rationale and design of a multicenter randomized controlled superiority trial. Trials. 2019. PMID: 31852491. doi:10.1186/s13063-019-3911-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。